The world of Wnt heads to Nas­daq as Sur­rozen an­nounces a $212M SPAC deal

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

An­oth­er day, an­oth­er SPAC merg­er in the world of biotech.

Less than 24 hours af­ter Tan­go Ther­a­peu­tics an­nounced its own leap to Nas­daq through the blank check route, Sur­rozen has de­cid­ed to take a sim­i­lar step. The Wnt path­way-fo­cused biotech is re­verse-merg­ing with Con­so­nance Cap­i­tal Man­age­ment’s SPAC in a $212 mil­lion deal, which in­cludes $92 mil­lion from the shell com­pa­ny and $120 mil­lion in PIPE fi­nanc­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER